Copyright Reports & Markets. All rights reserved.

Global Dilated Cardiomyopathy Therapeutic Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Dilated Cardiomyopathy Therapeutic
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Dilated Cardiomyopathy Therapeutic by Type
    • 1.3.1 Overview: Global Dilated Cardiomyopathy Therapeutic Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Dilated Cardiomyopathy Therapeutic Consumption Value Market Share by Type in 2023
    • 1.3.3 Aldosterone antagonists
    • 1.3.4 Angiotensin-converting enzyme (ACE) inhibitors
    • 1.3.5 Angiotensin II receptor blockers (ARBs)
    • 1.3.6 Beta-blockers
  • 1.4 Global Dilated Cardiomyopathy Therapeutic Market by Application
    • 1.4.1 Overview: Global Dilated Cardiomyopathy Therapeutic Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospitals
    • 1.4.3 Academic Institutions
  • 1.5 Global Dilated Cardiomyopathy Therapeutic Market Size & Forecast
  • 1.6 Global Dilated Cardiomyopathy Therapeutic Market Size and Forecast by Region
    • 1.6.1 Global Dilated Cardiomyopathy Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Dilated Cardiomyopathy Therapeutic Market Size by Region, (2019-2030)
    • 1.6.3 North America Dilated Cardiomyopathy Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Dilated Cardiomyopathy Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.6 South America Dilated Cardiomyopathy Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Dilated Cardiomyopathy Therapeutic Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Array BioPharma, Inc.
    • 2.1.1 Array BioPharma, Inc. Details
    • 2.1.2 Array BioPharma, Inc. Major Business
    • 2.1.3 Array BioPharma, Inc. Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.1.4 Array BioPharma, Inc. Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Array BioPharma, Inc. Recent Developments and Future Plans
  • 2.2 AstraZeneca plc.
    • 2.2.1 AstraZeneca plc. Details
    • 2.2.2 AstraZeneca plc. Major Business
    • 2.2.3 AstraZeneca plc. Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.2.4 AstraZeneca plc. Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 AstraZeneca plc. Recent Developments and Future Plans
  • 2.3 Celladon Corporation
    • 2.3.1 Celladon Corporation Details
    • 2.3.2 Celladon Corporation Major Business
    • 2.3.3 Celladon Corporation Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.3.4 Celladon Corporation Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Celladon Corporation Recent Developments and Future Plans
  • 2.4 GlaxoSmithKline plc
    • 2.4.1 GlaxoSmithKline plc Details
    • 2.4.2 GlaxoSmithKline plc Major Business
    • 2.4.3 GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.4.4 GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 GlaxoSmithKline plc Recent Developments and Future Plans
  • 2.5 Janssen Pharmaceuticals, Inc. (J&J)
    • 2.5.1 Janssen Pharmaceuticals, Inc. (J&J) Details
    • 2.5.2 Janssen Pharmaceuticals, Inc. (J&J) Major Business
    • 2.5.3 Janssen Pharmaceuticals, Inc. (J&J) Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.5.4 Janssen Pharmaceuticals, Inc. (J&J) Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Janssen Pharmaceuticals, Inc. (J&J) Recent Developments and Future Plans
  • 2.6 Merck & Co., Inc.
    • 2.6.1 Merck & Co., Inc. Details
    • 2.6.2 Merck & Co., Inc. Major Business
    • 2.6.3 Merck & Co., Inc. Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.6.4 Merck & Co., Inc. Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Merck & Co., Inc. Recent Developments and Future Plans
  • 2.7 Novartis International AG
    • 2.7.1 Novartis International AG Details
    • 2.7.2 Novartis International AG Major Business
    • 2.7.3 Novartis International AG Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.7.4 Novartis International AG Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Novartis International AG Recent Developments and Future Plans
  • 2.8 Pfizer, Inc.
    • 2.8.1 Pfizer, Inc. Details
    • 2.8.2 Pfizer, Inc. Major Business
    • 2.8.3 Pfizer, Inc. Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.8.4 Pfizer, Inc. Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Pfizer, Inc. Recent Developments and Future Plans
  • 2.9 Sanofi S.A.
    • 2.9.1 Sanofi S.A. Details
    • 2.9.2 Sanofi S.A. Major Business
    • 2.9.3 Sanofi S.A. Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.9.4 Sanofi S.A. Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Sanofi S.A. Recent Developments and Future Plans
  • 2.10 Teva Pharmaceutical Industries Ltd.
    • 2.10.1 Teva Pharmaceutical Industries Ltd. Details
    • 2.10.2 Teva Pharmaceutical Industries Ltd. Major Business
    • 2.10.3 Teva Pharmaceutical Industries Ltd. Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.10.4 Teva Pharmaceutical Industries Ltd. Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
  • 2.11 Vericel Corporation
    • 2.11.1 Vericel Corporation Details
    • 2.11.2 Vericel Corporation Major Business
    • 2.11.3 Vericel Corporation Dilated Cardiomyopathy Therapeutic Product and Solutions
    • 2.11.4 Vericel Corporation Dilated Cardiomyopathy Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Vericel Corporation Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Dilated Cardiomyopathy Therapeutic Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Dilated Cardiomyopathy Therapeutic by Company Revenue
    • 3.2.2 Top 3 Dilated Cardiomyopathy Therapeutic Players Market Share in 2023
    • 3.2.3 Top 6 Dilated Cardiomyopathy Therapeutic Players Market Share in 2023
  • 3.3 Dilated Cardiomyopathy Therapeutic Market: Overall Company Footprint Analysis
    • 3.3.1 Dilated Cardiomyopathy Therapeutic Market: Region Footprint
    • 3.3.2 Dilated Cardiomyopathy Therapeutic Market: Company Product Type Footprint
    • 3.3.3 Dilated Cardiomyopathy Therapeutic Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Dilated Cardiomyopathy Therapeutic Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Dilated Cardiomyopathy Therapeutic Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Dilated Cardiomyopathy Therapeutic Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Dilated Cardiomyopathy Therapeutic Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Dilated Cardiomyopathy Therapeutic Consumption Value by Type (2019-2030)
  • 6.2 North America Dilated Cardiomyopathy Therapeutic Consumption Value by Application (2019-2030)
  • 6.3 North America Dilated Cardiomyopathy Therapeutic Market Size by Country
    • 6.3.1 North America Dilated Cardiomyopathy Therapeutic Consumption Value by Country (2019-2030)
    • 6.3.2 United States Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Dilated Cardiomyopathy Therapeutic Consumption Value by Type (2019-2030)
  • 7.2 Europe Dilated Cardiomyopathy Therapeutic Consumption Value by Application (2019-2030)
  • 7.3 Europe Dilated Cardiomyopathy Therapeutic Market Size by Country
    • 7.3.1 Europe Dilated Cardiomyopathy Therapeutic Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.3 France Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Dilated Cardiomyopathy Therapeutic Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Dilated Cardiomyopathy Therapeutic Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region
    • 8.3.1 Asia-Pacific Dilated Cardiomyopathy Therapeutic Consumption Value by Region (2019-2030)
    • 8.3.2 China Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.5 India Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Dilated Cardiomyopathy Therapeutic Consumption Value by Type (2019-2030)
  • 9.2 South America Dilated Cardiomyopathy Therapeutic Consumption Value by Application (2019-2030)
  • 9.3 South America Dilated Cardiomyopathy Therapeutic Market Size by Country
    • 9.3.1 South America Dilated Cardiomyopathy Therapeutic Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Dilated Cardiomyopathy Therapeutic Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Dilated Cardiomyopathy Therapeutic Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country
    • 10.3.1 Middle East & Africa Dilated Cardiomyopathy Therapeutic Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Dilated Cardiomyopathy Therapeutic Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Dilated Cardiomyopathy Therapeutic Market Drivers
  • 11.2 Dilated Cardiomyopathy Therapeutic Market Restraints
  • 11.3 Dilated Cardiomyopathy Therapeutic Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Dilated Cardiomyopathy Therapeutic Industry Chain
  • 12.2 Dilated Cardiomyopathy Therapeutic Upstream Analysis
  • 12.3 Dilated Cardiomyopathy Therapeutic Midstream Analysis
  • 12.4 Dilated Cardiomyopathy Therapeutic Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Dilated Cardiomyopathy Therapeutic market size was valued at USD 328.7 million in 2023 and is forecast to a readjusted size of USD 423.4 million by 2030 with a CAGR of 3.7% during review period.
    Dilated cardiomyopathy (DCM) is characterized by LV (left ventricular) or biventricular systolic dysfunction and dilation, not explained by abnormal loading conditions or coronary artery disease.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    The Global Info Research report includes an overview of the development of the Dilated Cardiomyopathy Therapeutic industry chain, the market status of Hospitals (Aldosterone antagonists, Angiotensin-converting enzyme (ACE) inhibitors), Academic Institutions (Aldosterone antagonists, Angiotensin-converting enzyme (ACE) inhibitors), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Dilated Cardiomyopathy Therapeutic.
    Regionally, the report analyzes the Dilated Cardiomyopathy Therapeutic markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Dilated Cardiomyopathy Therapeutic market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Dilated Cardiomyopathy Therapeutic market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Dilated Cardiomyopathy Therapeutic industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Aldosterone antagonists, Angiotensin-converting enzyme (ACE) inhibitors).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Dilated Cardiomyopathy Therapeutic market.
    Regional Analysis: The report involves examining the Dilated Cardiomyopathy Therapeutic market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Dilated Cardiomyopathy Therapeutic market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Dilated Cardiomyopathy Therapeutic:
    Company Analysis: Report covers individual Dilated Cardiomyopathy Therapeutic players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Dilated Cardiomyopathy Therapeutic This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Academic Institutions).
    Technology Analysis: Report covers specific technologies relevant to Dilated Cardiomyopathy Therapeutic. It assesses the current state, advancements, and potential future developments in Dilated Cardiomyopathy Therapeutic areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Dilated Cardiomyopathy Therapeutic market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Dilated Cardiomyopathy Therapeutic market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    Aldosterone antagonists
    Angiotensin-converting enzyme (ACE) inhibitors
    Angiotensin II receptor blockers (ARBs)
    Beta-blockers
    Market segment by Application
    Hospitals
    Academic Institutions
    Market segment by players, this report covers
    Array BioPharma, Inc.
    AstraZeneca plc.
    Celladon Corporation
    GlaxoSmithKline plc
    Janssen Pharmaceuticals, Inc. (J&J)
    Merck & Co., Inc.
    Novartis International AG
    Pfizer, Inc.
    Sanofi S.A.
    Teva Pharmaceutical Industries Ltd.
    Vericel Corporation
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Dilated Cardiomyopathy Therapeutic product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Dilated Cardiomyopathy Therapeutic, with revenue, gross margin and global market share of Dilated Cardiomyopathy Therapeutic from 2019 to 2024.
    Chapter 3, the Dilated Cardiomyopathy Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Dilated Cardiomyopathy Therapeutic market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Dilated Cardiomyopathy Therapeutic.
    Chapter 13, to describe Dilated Cardiomyopathy Therapeutic research findings and conclusion.

    Buy now